Chief Financial Officer · Starling Oncology, Inc. (STLN)

Scott Dalgleish

A named executive officer of Starling Oncology in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,758,691

Salary $250,000Stock awards $879,502Bonus $4,171

FY2020: $317,583

3rd of 3 named executive officers at Starling Oncology by FY2021 total.

3 named officers on file for Starling Oncology, FY2021

Scott Dalgleish’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Starling Oncology’s whole pay program stands against its peers

  • Starling Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STLN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 3, 2022 (DEF 14A).

Free

Get Scott Dalgleish’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Scott Dalgleish compensation by year

Starling Oncology Summary Compensation Table · all 2 fiscal years held
In US dollars, as Starling Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$76,515$250,000
Bonus$0$4,171
Stock awards$0$879,502
Option awards$232,944$3,571,918
Non-equity incentive$8,124$41,500
Pension and deferred compensation$0$0
All other$0$11,600
Total$317,583$4,758,691

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Starling Oncology, Inc. DEF 14A filed June 3, 2022, accession 0001193125-22-166799, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Starling Oncology, Inc. filed document, accession 0001193125-22-166799. Every figure is read from that document and cited to the page and table it appears in. Filed June 3, 2022.

$318K
$4.8M
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU71,350$695,663—
RSU47,566$463,769—
Option190,331—$0.86
Option341,130—$0.86

Per the Outstanding Equity Awards at Fiscal Year-End table in Starling Oncology, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Starling Oncology’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Brad HivelyPrevious Chief Executive Officer$11,635,536
Daniel VirnichChief Executive Officer$7,625,667
Scott Dalgleish · this pageChief Financial Officer$4,758,691

The full Starling Oncology compensation record

free company brief

This page is one person within Starling Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Starling Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Scott Dalgleish's compensation dossier · One-time report. No refunds.